Tech Company Financing Transactions

Zura Bio Funding Round

Zura Bio closed a $80 million venture capital round on 6/6/2023. Investors included Deep Track Capital, Great Point Partners and Suvretta Capital Management.

Transaction Overview

Company Name
Zura Bio
Announced On
6/6/2023
Transaction Type
Venture Equity
Amount
$80,000,000
Round
Undisclosed
Investors

Deep Track Capital (Lead Investor)

Great Point Partners (Lead Investor)

Suvretta Capital Management (Lead Investor)

Proceeds Purpose
The company intends to use the funds to initiate a Phase 2 clinical trial for ZB-106 in systemic sclerosis (SSc), followed by a Phase 2 clinical trial in hidradenitis suppurativa (HS).

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
4225 Executive Square 600
San--Diego, CA 92037
USA
Phone
(858) 247-0520
Website
www.zurabio.com
Email Address
[email protected]
Overview
Zura Bio Limited is a clinical-stage biotechnology company advancing immunology assets into Phase 2 development programs, including ZB-168 and Torudokimab. ZB-168 is an anti IL7R a inhibitor that has the potential to impact diseases driven by IL7 and TSLP biological pathways. Zura aims to develop a portfolio of therapeutic indications for ZB-168 which build on existing Phase 1b data in Type 1 Diabetes demonstrating a favorable safety profile and strong biological rationale. Torudokimab is a fully human, high affinity monoclonal antibody that neutralizes IL33 and is currently at the Phase 2 clinical development stage.
Profile
Zura Bio LinkedIn Company Profile
Social Media
Zura Bio Company Twitter Account
Company News
Zura Bio News
Facebook
Zura Bio on Facebook
YouTube
Zura Bio on YouTube

Management Team

Title
Name
Email & Social
Chairman
Amit Munshi
  Amit Munshi LinkedIn Profile  Amit Munshi Twitter Account  Amit Munshi News  Amit Munshi on Facebook
Chief Executive Officer
Someit Sidhu
  Someit Sidhu LinkedIn Profile  Someit Sidhu Twitter Account  Someit Sidhu News  Someit Sidhu on Facebook
Chief Financial Officer
Verender Badial
  Verender Badial LinkedIn Profile  Verender Badial Twitter Account  Verender Badial News  Verender Badial on Facebook
Chief Medical Officer
Chris Cabell
  Chris Cabell LinkedIn Profile  Chris Cabell Twitter Account  Chris Cabell News  Chris Cabell on Facebook
Chief Scientific Officer
Michael Howell
  Michael Howell LinkedIn Profile  Michael Howell Twitter Account  Michael Howell News  Michael Howell on Facebook
Chief Technical Officer
Gary Whale
  Gary Whale LinkedIn Profile  Gary Whale Twitter Account  Gary Whale News  Gary Whale on Facebook

 

 

Browse more venture capital transactions:

Prev: 6/5/2023: Beyond Music venture capital transaction
Next: 6/6/2023: Candy Funhouse venture capital transaction

 

Share this article

 

News on VC Transactions

We do our best to report on tech company VC transactions. VC investment data records on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.